1. Ahrén B., Gomis R., Standl E., Mills D., Schweizer A. Diabetes Care, 27, 2874-80 (2004).
2. Alba M., Ahrén B, Inzucchi S.E., Guan Y, Mallick M., Xu L., O'Neill E.A., Williams-Herman D.E., Kaufman K.D., Goldstein B.J. Diabetes Obes Metab, 15, 1101-10 (2013).
3. Takeda Pharmaceutical Co. Ltd. Alogliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2010/P202000029/index.html> (2010). Accessed 9 April 2019.
4. Amin N.B., Wang X., Jain S.M., Lee D.S., Nucci G., Rusnak J.M. Diabetes Obes Metab, 17, 591-8 (2015).
5. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E.; Sitagliptin Study 021 Group. Diabetes Care, 29, 2632-7 (2006).
6. Ba J., Han P, Yuan G., Mo Z., Pan C., Wu F., Xu L., Hanson M.E., Engel S.S., Shankar R.R. J Diabetes, 9, 667-76 (2017).
7. Bajaj M., Gilman R., Patel S., Kempthorne-Rawson J., Lewis-D'Agostino D., Woerle H.J. Diabet Med, 31, 1505-14 (2014).
8. Barnett A.H., Patel S., Harper R., Toorawa R., Thiemann S., von Eynatten M., Woerle H.J. Diabetes Obes Metab, 14, 1145-54 (2012).
9. Bosi E., Camisasca R.P., Collober C., Rochotte E., Garber A.J. Diabetes Care, 30, 890-5 (2007).
10. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G.; Sitagliptin Study 020 Group. Diabetes Care, 29, 2638-43 (2006).
11. Chen Y., Ning G., Wang C., Gong Y., Patel S., Zhang C., Izumoto T., Woerle H.J., Wang W. J Diabetes Investig, 6, 692-8 (2015).
12. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q.; Alogliptin Study 010 Group. Diabetes Care, 31, 2315-7 (2008).
13. DeFronzo R.A., Hissa M.N., Garber A.J., Luiz Gross J , Yuyan Duan R., Ravichandran S., Chen R.S.; Saxagliptin 014 Study Group. Diabetes Care, 32, 1649-55 (2009).
14. Dejager S., Razac S., Foley J.E., Schweizer A. Horm Metab Res, 39, 218-23 (2007).
15. Del Prato S., Barnett A.H., Huisman H., Neubacher D., Woerle H.J., Dugi K.A. Diabetes Obes Metab, 13, 258-67 (2011).
16. Dobs A.S., Goldstein B.J., Aschner P., Horton E.S., Umpierrez G.E., Duran L., Hill J.S., Chen Y., Golm G.T., Langdon R.B., Williams-Herman D.E., Kaufman K.D., Amatruda J.M., Ferreira J.C. J Diabetes, 5, 68-79 (2013).
17. Fonseca V., Staels B., Morgan J.D. 2nd, Shentu Y., Golm G.T., Johnson-Levonas A.O., Kaufman K.D., Goldstein B.J., Steinberg H.. J Diabetes Complications, 27, 177-83 (2013).
18. Forst T., Uhlig-Laske B., Ring A., Graefe-Mody U., Friedrich C., Herbach K., Woerle H.J., Dugi K.A. Diabet Med, 27, 1409-19 (2010).
19. Frederich R., McNeill R., Berglind N., Fleming D., Chen, R. Diabetol Metab Syndr, 4, 36 (2012).
20. Garber A.J., Foley J.E., Banerji M.A., Ebeling P., Gudbjörnsdottir S., Camisasca R.P., Couturier A., Baron M.A. Diabetes Obes Metab, 10, 1047-56 (2008).
21. Goldstein B.J., Feinglos M.N., Lunceford J.K., Johnson J., Williams-Herman D.E.; Sitagliptin 036 Study Group. Diabetes Care, 30, 1979-87 (2007).
22. Haak T., Meinicke T., Jones R., Weber S., von Eynatten M., Woerle H.J. Diabetes Obes Metab, 14, 565-74 (2012).
23. Hanefeld M., Herman G.A., Wu M., Mickel C., Sanchez M., Stein P.P.; Sitagliptin Study 014 Investigators. Curr Med Res Opin, 23, 1329-39 (2007).
24. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P.; Sitagliptin Study 035 Group. Diabetes Obes Metab, 9, 733-45 (2007).
25. Hollander P., Li J., Allen E., Chen R.; CV181-013 Investigators. J Clin Endocrinol Metab, 94, 4810-9 (2009).
26. Hong S., Park C.Y., Han K.A., Chung C.H., Ku B.J., Jang H.C., Ahn C.W., Lee M.K., Moon M.K., Son H.S., Lee C.B., Cho Y.W., Park S.W. Diabetes Obes Metab, 18, 528-32 (2016).
27. Ji L., Han P., Wang X., Liu J., Zheng S., Jou Y.M., O'Neill E.A., Golm G.T., Engel S.S., Kaufman K.D., Shankar R.R. J Diabetes Investig, 7, 727-36 (2016).
28. Jung C.H., Park C.Y., Ahn K.J., Kim N.H., Jang H.C., Lee M.K., Park J.Y., Chung C H., Min K.W., Sung Y.A., Park J.H., Kim S.J., Lee H.J., Park S.W Diabetes Metab Res Rev, 31, 295-306 (2015).
29. Kim M.K., Rhee E.J., Han K.A., Woo A.C., Lee M.K., Ku B J., Chung C.H., Kim K.A., Lee H.W., Park I.B., Park J.Y., Chul Jang H.C., Park K.S., Jang W.I., Cha B.Y. Diabetes Obes Metab, 17, 309-12 (2015).
30. Lavalle-González F.J., Januszewicz A., Davidson J , Tong C., Qiu R., Canovatchel W., Meininger G. Diabetologia, 56, 2582-92 (2013).
31. Lewin A.J., Arvay L., Liu D., Patel S., von Eynatten M., Woerle H.J. Clin Ther, 34, 1909-19 e15 (2012).
32. Boehringer Ingelheim. Linagliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2011/P201100128/index.html> (2011). Accessed 9 April 2019.
33. Matthaei S., Catrinoiu D., Celiński A., Ekholm E., Cook W., Hirshberg B., Chen H., Iqbal N., Hansen L. Diabetes Care, 38, 2018-24 (2015).
34. Mohan V., Yang W., Son H.Y., Xu L., Noble L., Langdon R.B., Amatruda J.M., Stein P.P., Kaufman K.D. Diabetes Res Clin Pract, 83, 106-16 (2009).
35. Moses R.G., Kalra S., Brook D., Sockler J., Monyak J., Visvanathan J., Montanaro M., Fisher SA. Diabetes Obes Metab, 16, 443-50 (2014).
36. Nauck M.A., Ellis G.C., Fleck P.R., Wilson C.A., Mekki Q.; Alogliptin Study 008 Group. Int J Clin Pract, 63, 46-55 (2009).
37. Nauck M., Weinstock R.S., Umpierrez G.E., Guerci B., Skrivanek Z., Milicevic, Z. Diabetes Care, 37, 2149-58 (2014).
38. Owens D.R., Swallow R., Dugi K.A., Woerle H.J. Diabet Med, 28, 1352-61 (2011).
39. Pan C.Y., Yang W., Tou C., Gause-Nilsson I., Zhao, J. Diabetes Metab Res Rev, 28, 268-75 (2012).
40. Pi-Sunyer F.X., Schweizer A., Mills D., Dejager S. Diabetes Res Clin Pract, 76, 132-8 (2007).
41. Pratley R.E., Kipnes M.S., Fleck P.R., Wilson C., Mekki Q; Alogliptin Study 007 Group. Diabetes Obes Metab, 11, 167-76 (2009).
42. Pratley R.E , Reusch J.E., Fleck P.R., Wilson C.A., Mekki Q; Alogliptin Study 009 Group. Curr Med Res Opin, 25, 2361-71 (2009).
43. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H.; Sitagliptin Study 023 Group. Diabetologia, 49, 2564-71 (2006).
44. Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., Amatruda J.M., Langdon R.B., Stein P.P., Alba M. Curr Med Res Opin, 24, 537-50 (2008).
45. Rhee E.J., Lee W.Y., Yoon K.H., Yoo S.J., Lee I.K., Baik S.H., Kim Y.K., Lee M.K., Park K.S., Park J.Y., Cha B.S., Lee H.W., Min K.W., Bae H.Y., Kim M.J., Kim J.A., Kim D.K., Kim S.W. Diabetes Obes Metab, 12, 1113-9 (2010).
46. Ristic S., Byiers S., Foley J., Holmes D. Diabetes Obes Metab, 7, 692-8 (2005).
47. Roden M., Weng J., Eilbracht J., Delafont B., Kim G., Woerle H.J., Broedl U.C.; EMPA-REG MONO trial investigators. Lancet Diabetes Endocrinol, 1, 208-19 (2013).
48. Rosenstock J., Brazg R., Andryuk P.J., Lu K., Stein P. Clin Ther, 28, 1556-68 (2006).
49. Rosenstock J., Sankoh S., List J.F. Diabetes Obes Metab, 10, 376-86 (2008).
50. Rosenstock J., Aguilar-Salinas C., Klein E., Nepal S., List J., Chen R.; CV181-011 Study Investigators. Curr Med Res Opin, 25, 2401-11 (2009).
51. Rosenstock J., Rendell M.S., Gross J.L., Fleck P.R., Wilson C.A., Mekki Q. Diabetes Obes Metab, 11, 1145-52 (2009).
52. Ross S.A., Rafeiro E., Meinicke T., Toorawa R., Weber-Born S., Woerle H.J. Curr Med Res Opin, 28, 1465-74 (2012).
53. Otsuka Pharmaceutical Co. Ltd. Saxagliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2013/P201300036/index.html> (2013). Accessed 9 April 2019.
54. Scherbaum W.A., Schweizer A., Mari A., Nilsson P.M., Lalanne G., Jauffret S., Foley J.E. Diabetes Obes Metab, 10, 675-82 (2008).
55. Scott R., Loeys T., Davies M.J., Engel S.S.; Sitagliptin Study 801 Group. Diabetes Obes Metab, 10, 959-69 (2008).
56. Smits M.M., Tonneijck L., Muskiet M.H., Hoekstra T., Kramer M.H., Diamant M., Nieuwdorp M., Groen A.K., Cahen D.L., van Raalte D.H. Diabetes Obes Metab, 18, 1217-25 (2016).
57. Taskinen M.R., Rosenstock J., Tamminen I., Kubiak R., Patel S., Dugi K.A., Woerle H.J. Diabetes Obes Metab, 13, 65-74 (2011).
58. Mitsubishi Tanabe Pharma Corporation. Teneligliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2012/P201200070/index.html> (2012). Accessed 9 April 2019.
59. Thrasher J., Daniels K., Patel S., Whetteckey J., Woerle H.J. Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study. Endocr Pract, 20, 412-20 (2014).
60. Tinahones F.J., Gallwitz B., Nordaby M., Götz S., Maldonado-Lutomirsky M., Woerle H.J., Broedl U.C. Diabetes Obes Metab, 19, 266-74 (2017). (Study 1)
61. Tinahones F.J., Gallwitz B., Nordaby M., Götz S., Maldonado-Lutomirsky M., Woerle H.J., Broedl U.C. Diabetes Obes Metab, 19, 266-74 (2017). (Study 2)
62. Vilsbøll T., Rosenstock J., Yki-Järvinen H., Cefalu W.T., Chen Y., Luo E., Musser B., Andryuk P.J., Ling Y., Kaufman K.D., Amatruda J.M., Engel S.S., Katz L. Diabetes Obes Metab, 12, 167-77 (2010).
63. Wang W., Yang J., Yang G., Gong Y., Patel S., Zhang C., Izumoto T., Ning G. J Diabetes, 8, 229-37 (2016).
64. Wang W., Ning G., Ma J., Liu X., Zheng S., Wu F., Xu L., O'Neill E.A., Fujita K.P., Engel S.S., Kaufman K.D., Shankar R.R. Curr Med Res Opin, 33, 693-9 (2017).
65. Yang W., Pan C.Y., Tou C., Zhao J., Gause-Nilsson I. Diabetes Res Clin Pract, 94, 217-24 (2011).
66. Yang W., Guan Y., Shentu Y., Li Z., Johnson-Levonas A.O., Engel S.S., Kaufman K.D., Goldstein B.J., Alba M. J Diabetes, 4, 227-37 (2012).
67. Yang S.J., Min K.W., Gupta S.K., Park J.Y., Shivane V.K., Pitale S.U., Agarwal P.K., Sosale A., Gandhi P., Dharmalingam M., Mohan V., Mahesh U., Kim D.M., Kim Y.S., Kim J.A., Kim P.K., Baik S.H. Diabetes Obes Metab, 15, 410-6 (2013).
68. Yang W., Xing X., Lv X., Li Y., Ma J., Yuan G., Sun F., Wang W., Woloschak M., Lukashevich V, Kozlovski P., Kothny W.; all investigators. J Diabetes, 7, 174-81 (2015).
69. Yki-Järvinen H., Rosenstock J., Durán-Garcia S., Pinnetti S., Bhattacharya S., Thiemann S., Patel S., Woerle H.J. Diabetes Care, 36, 3875-81 (2013).
70. Takeda Pharmaceutical Co. Ltd. Alogliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2010/P202000029/index.html> (2010). Accessed 9 April 2019.
71. Pharmaceuticals and Medical Devices Agency. Alogliptin review report (in Japanese). <http://www.pmda.go.jp/drugs/2011/P201100038/400256000_22200AMX00309_A100_2.pdf> (2011). Accessed 25 June 2019.
72. Inagaki N., Onouchi H., Maezawa H., Kuroda S., Kaku K. Lancet Diabetes Endocrinol, 3, 191-7 (2015).
73. Iwamoto Y., Taniguchi T., Nonaka K., Okamoto T., Okuyama K., Ferreira J.C., Amatruda J. Endocrine journal, 57, 383-94 (2010).
74. Kadowaki T., Tajima N., Odawara M., Nishii M., Taniguchi T., Ferreira J.C. J Diabetes Investig, 4, 174-81 (2013).
75. Kadowaki T., Tajima N., Odawara M., Minamide T., Kawashima M., Yanagida D., Okamoto T., Ferreira J.C. Diabetol Int, 4, 160-72 (2013).
76. Kadowaki T., Kondo K. Diabetes Obes Metab, 16, 418-25 (2014).
77. Kadowaki T., Kondo K. Diabetes Obes Metab, 15, 810-8 (2013).
78. Kaku K., Itayasu T., Hiroi S., Hirayama M., Seino Y. Diabetes Obes Metab, 13, 1028-35 (2011).
79. Kaku K., Mori M., Kanoo T., Katou M., Seino Y. Expert Opin Pharmacother, 15, 2121-30 (2014).
80. Kashiwagi A., Kadowaki T., Tajima N., Nonaka K., Taniguchi T., Nishii M., Ferreira J.C., Amatruda J.M.. J Diabetes Investig, 2, 381-90 (2011).
81. Kawamori R., Inagaki N., Araki E., Watada H., Hayashi N., Horie Y., Sarashina A., Gong Y., von Eynatten M., Woerle H.J., Dugi K.A. Diabetes Obes Metab, 14, 348-57 (2012).
82. Novartis Pharma K.K. Vildagliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2010/P201000008/index.html> (2010). Accessed 9 April 2019.
83. Nonaka K., Kakikawa T., Sato A., Okuyama K., Fujimoto G., Kato N., Suzuki H., Hirayama Y., Ahmed T., Davies M.J., Stein P.P. Diabetes Res Clin Pract, 79, 291-8 (2008).
84. Seino Y., Fujita T., Hiroi S., Hirayama M., Kaku K. Curr Med Res Opin, 27 Suppl 3, 21-9 (2011).
85. Seino Y., Miyata Y., Hiroi S., Hirayama M., Kaku K. Diabetes Obes Metab, 14, 927-36 (2012).
86. Seino, Y. Jpn Pharmacol Ther, 42, 503-18 (2014). (262-08-001)
87. Seino, Y. Jpn Pharmacol Ther, 42, 503-18 (2014). (262-09-001)
88. MSD K.K. a subsidiary of Merck & Co. Inc. Kenilworth, N.J., USA. Ono Pharmaceutical Co. Ltd. Sitagliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2009/P200900043/index.html> (2009). Accessed 9 April 2019.
89. Pharmaceuticals and Medical Devices Agency. Sitagliptin review report (in Japanese). <http://www.pmda.go.jp/drugs/2014/P201400069/180188000_22100AMX02260_A100_1.pdf> (2014). Accessed 25 June 2019.
90. Pharmaceuticals and Medical Devices Agency. Sitagliptin review report (in Japanese). <http://www.pmda.go.jp/drugs/2011/P201100098/17005000_22100AMX02257_A001_1.pdf> (2011). Accessed 25 June 2019.
91. Mitsubishi Tanabe Pharma Corporation. Teneligliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2012/P201200070/index.html> (2012). Accessed 9 April 2019.
92. Mitsubishi Tanabe Pharma Corporation. Teneligliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2012/P201200070/index.html> (2012). Accessed 9 April 2019.
93. Mitsubishi Tanabe Pharma Corporation. Teneligliptin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2012/P201200070/index.html> (2012). Accessed 9 April 2019.
94. Bailey C.J., Iqbal N., T'Joen C., List J.F. Diabetes Obes Metab, 14, 951-9 (2012).
95. Bailey C.J., Gross J.L., Pieters A., Bastien A., List J.F. Lancet, 375, 2223-33 (2010).
96. Bolinder J., Ljunggren Ö., Kullberg J., Johansson L., Wilding J., Langkilde A.M., Sugg J., Parikh S. J Clin Endocrinol Metab, 97, 1020-31 (2012).
97. Mitsubishi Tanabe Pharma Corporation. Canagliflozin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2014/P201400070/index.html> (2014). Accessed 9 April 2019.
98. Bristol-Myers Squibb Company. Dapagliflozin new drug application (in Japanese). <http://www.pmda.go.jp/drugs/2014/P201400016/index.html> (2014). Accessed 9 April 2019.
99. Ferrannini E., Ramos S.J., Salsali A., Tang W., List J.F. Diabetes Care, 33, 2217-24 (2010).
100. Ferrannini E., Seman L., Seewaldt-Becker E., Hantel S., Pinnetti S., Woerle H.J. Diabetes Obes Metab, 15, 721-8 (2013).
101. Fonseca V.A., Ferrannini E., Wilding J.P., Wilpshaar W., Dhanjal P., Ball G., Klasen S. J Diabetes Complications, 27, 268-73 (2013).
102. Forst T., Guthrie R., Goldenberg R., Yee J., Vijapurkar U., Meininger G., Stein P. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab, 16, 467-77 (2014).
103. Fulcher G., Matthews D.R., Perkovic V., de Zeeuw D., Mahaffey K.W., Weiss R., Rosenstock J., Capuano G., Desai M., Shaw W., Vercruysse F., Meininger G., Neal B. Diabetes Ther, 6, 289-302 (2015).
104. Häring H.U., Merker L., Seewaldt-Becker E., Weimer M., Meinicke T., Broedl U.C., Woerle H.J.; EMPA-REG MET Trial Investigators. Diabetes Care, 37, 1650-9 (2014).
105. Häring H.U., Merker L., Seewaldt-Becker E., Weimer M., Meinicke T., Woerle H.J., Broedl U.C.; EMPA-REG METSU Trial Investigators. Diabetes Care, 36, 3396-404 (2013).
106. Jabbour S.A., Hardy E., Sugg J., Parikh S. Diabetes Care, 37, 740-50 (2014).
107. Ji L., Ma J., Li H., Mansfield T.A., T'joen C.L., Iqbal N., Ptaszynska A., List J.F. Clin Ther, 36, 84-100 e9 (2014).
108. Ji L., Han P., Liu Y., Yang G., Dieu Van N.K., Vijapurkar U., Qiu R., Meininger G. Diabetes Obes Metab, 17, 23-31 (2015).
109. Kovacs C.S., Seshiah V., Swallow R., Jones R., Rattunde H., Woerle H.J., Broedl U.C.; EMPA-REG PIO™ trial investigators. Diabetes Obes Metab, 16, 147-58 (2014).
110. Lavalle-González F.J., Januszewicz A., Davidson J , Tong C., Qiu R., Canovatchel W., Meininger G. Diabetologia, 56, 2582-92 (2013).
111. List J.F., Woo V., Morales E., Tang W., Fiedorek F.T. Diabetes Care, 32, 650-7 (2009).
112. Lu C.H., Min K.W., Chuang L.M., Kokubo S., Yoshida S., Cha B.S. J Diabetes Investig, 7, 366-73 (2016).
113. Mathieu C., Ranetti A.E., Li D., Ekholm E., Cook W., Hirshberg B., Chen H., Hansen L., Iqbal N. Diabetes Care, 38, 2009-17 (2015).
114. Matthaei S., Bowering K., Rohwedder K., Grohl A., Parikh S. Diabetes Care, 38, 365-72 (2015).
115. Neal B., Perkovic V., de Zeeuw D., Mahaffey K.W., Fulcher G., Ways K., Desai M., Shaw W., Capuano G., Alba M., Jiang J., Vercruysse F., Meininger G., Matthews D.; CANVAS Trial Collaborative Group. Diabetes Care, 38, 403-11 (2015).
116. Roden M., Weng J., Eilbracht J., Delafont B., Kim G., Woerle H.J., Broedl U.C.; EMPA-REG MONO trial investigators. Lancet Diabetes Endocrinol, 1, 208-19 (2013).
117. Rosenstock J., Aggarwal N., Polidori D., Zhao Y., Arbit D., Usiskin K., Capuano G., Canovatchel W.; Canagliflozin DIA 2001 Study Group. Diabetes Care, 35, 1232-8 (2012).
118. Rosenstock J., Vico M., Wei L., Salsali A., List J.F. Diabetes Care, 35, 1473-8 (2012).
119. Rosenstock J., Seman L.J., Jelaska A., Hantel S., Pinnetti S., Hach T., Woerle H.J. Diabetes Obes Metab, 15, 1154-60 (2013).
120. Rosenstock J., Jelaska A., Frappin G., Salsali A., Kim G., Woerle H.J., Broedl U.C.; EMPA-REG MDI Trial Investigators. Diabetes Care, 37, 1815-23 (2014).
121. Rosenstock J., Jelaska A., Zeller C., Kim G., Broedl U.C., Woerle H.J.; EMPA-REG BASALTM trial investigators. Diabetes Obes Metab, 17, 936-48 (2015).
122. Ross S., Thamer C., Cescutti J., Meinicke T., Woerle H.J., Broedl U.C. Diabetes Obes Metab, 17, 699-702 (2015).
123. Schumm-Draeger P.M., Burgess L., Koranyi L., Hruba V., Hamer-Maansson J.E., de Bruin T.W. Diabetes Obes Metab, 17, 42-51 (2015).
124. Sha S., Polidori D., Heise T., Natarajan J., Farrell K., Wang S.S., Sica D., Rothenberg P., Plum-Mörschel L. Diabetes Obes Metab, 16, 1087-95 (2014).
125. Softeland E., Meier J.J., Vangen B., Toorawa R., Maldonado-Lutomirsky M., Broedl U.C. Diabetes Care, 40, 201-9 (2017).
126. Stenlöf K., Cefalu W.T., Kim K.A , Alba M., Usiskin K., Tong C., Canovatchel W., Meininger G. Diabetes Obes Metab, 15, 372-82 (2013).
127. Strojek K., Yoon K.H., Hruba V., Elze M., Langkilde A.M , Parikh S. Diabetes Obes Metab, 13, 928-38 (2011).
128. Terra S.G., Focht K., Davies M., Frias J., Derosa G., Darekar A., Golm G., Johnson J., Saur D., Lauring B., Dagogo-Jack S. Diabetes Obes Metab, 19, 721-8 (2017).
129. Tikkanen I., Narko K., Zeller C., Green A., Salsali A., Broedl U.C., Woerle H.J ; EMPA-REG BP Investigators. Diabetes Care, 38, 420-8 (2015).
130. Weber M.A., Mansfield T.A , Alessi F., Iqbal N., Parikh S., Ptaszynska A. Blood Press, 25, 93-103 (2016).
131. Weber M.A., Mansfield T.A., Cain V.A., Iqbal N., Parikh S , Ptaszynska A. Lancet Diabetes Endocrinol, 4, 211-20 (2016).
132. Wilding J.P., Woo V., Soler N.G., Pahor A., Sugg J., Rohwedder K., Parikh S ; Dapagliflozin 006 Study Group. Ann Intern Med, 156, 405-15 (2012).
133. Wilding J.P., Ferrannini E., Fonseca V.A., Wilpshaar W., Dhanjal P., Houzer A. Diabetes Obes Metab, 15, 403-9 (2013).
134. Wilding J.P., Charpentier G., Hollander P., González-Gálvez G., Mathieu C., Vercruysse F., Usiskin K., Law G., Black S., Canovatchel W., Meininger G. Int J Clin Pract, 67, 1267-82 (2013).
135. Yang W., Han P., Min K.W., Wang B., Mansfield T., T'Joen C., Iqbal N., Johnsson E., Ptaszynska A. J Diabetes, 8, 796-808 (2016).
136. Araki E., Onishi Y., Asano M., Kim H., Ekholm E., Johnsson E., Yajima T. J Diabetes Investig, 7, 555-64 (2016).
137. Inagaki N., Kondo K., Yoshinari T., Maruyama N., Susuta Y., Kuki H. Diabetes Obes Metab, 15, 1136-45 (2013).
138. Inagaki N., Kondo K., Yoshinari T., Takahashi N., Susuta Y., Kuki H. Expert Opin Pharmacother, 15, 1501-15 (2014).
139. Inagaki N., Harashima S., Maruyama N., Kawaguchi Y., Goda M., Iijima H. Cardiovasc Diabetol, 15, 89 (2016).
140. Ishihara H., Yamaguchi S., Nakao I., Okitsu A., Asahina S. Diabetes Obes Metab, 18, 1207-16 (2016).
141. Kadowaki T., Haneda M., Inagaki N., Terauchi Y., Taniguchi A., Koiwai K., Rattunde H., Woerle H.J., Broedl U.C. Adv Ther, 31, 621-38 (2014).
142. Kadowaki T., Inagaki N., Kondo K., Nishimura K., Kaneko G., Maruyama N., Nakanishi N., Iijima H., Watanabe Y., Gouda M. Diabetes Obes Metab, 19, 874-82 (2017).
143. Kaku K., Inoue S., Matsuoka O., Kiyosue A., Azuma H., Hayashi N., Tokudome T., Langkilde A.M., Parikh S. Diabetes Obes Metab, 15, 432-40 (2013).
144. Kaku K., Watada H., Iwamoto Y., Utsunomiya K., Terauchi Y., Tobe K., Tanizawa Y , Araki E., Ueda M., Suganami H., Watanabe D; Tofogliflozin 003 Study Group. Cardiovasc Diabetol, 13, 65 (2014).
145. Kaku K., Kiyosue A., Inoue S., Ueda N., Tokudome T., Yang J., Langkilde A.M. Diabetes Obes Metab, 16, 1102-10 (2014).
146. Kashiwagi A., Kazuta K., Yoshida S., Nagase I. J Diabetes Investig, 5, 382-91 (2014).
147. Kashiwagi A., Kazuta K., Takinami Y., Yoshida S., Utsuno A., Nagase I. Diabetol Int, 6, 8-18 (2014).
148. Kashiwagi A., Kazuta K., Goto K., Yoshida S., Ueyama E., Utsuno A. Diabetes Obes Metab, 17, 304-8 (2015).
149. Kashiwagi A., Shiga T., Akiyama N., Kazuta K., Utsuno A., Yoshida S., Ueyama E. Diabetol Int, 6, 104-16 (2014).
150. Kashiwagi A., Akiyama N., Shiga T., Kazuta K., Utsuno A., Yoshida S., Ueyama E. Diabetol Int, 6, 125-38 (2014).
151. Seino Y., Sasaki T., Fukatsu A., Sakai S., Samukawa Y. Curr Med Res Opin, 30, 1219-30 (2014).
152. Seino Y., Sasaki T., Fukatsu A., Ubukata M., Sakai S., Samukawa Y. Curr Med Res Opin, 30, 1231-44 (2014).
153. Seino Y., Sasaki T., Fukatsu A., Ubukata M., Sakai S., Samukawa Y. Curr Med Res Opin, 30, 1245-55 (2014).
154. Seino Y., Inagaki N., Haneda M., Kaku K., Sasaki T., Fukatsu A., Ubukata M., Sakai S., Samukawa Y. J Diabetes Investig, 6, 443-53 (2015).